Alkermes plc. Net Cash Provided by (Used in) Investing Activities, Continuing Operations
Alkermes plc. (ALKS) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of $15.46 million for the 3-month period ending 2017-03-31, per its 10-Q filed 2017-04-27.
Discontinued › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2017-04-27
- Alkermes plc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-03-31 was $15.46M, a 78.73% decline year-over-year.
- Alkermes plc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2016-12-31 was -$20.88M.
- Alkermes plc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2016-09-30 was $46.99M, a 54.02% increase year-over-year.
- Alkermes plc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2016-06-30 was $28.44M.
- Alkermes plc. net cash provided by (used in) investing activities, continuing operations for fiscal 2016 was $127.24M.
- Alkermes plc. net cash provided by (used in) investing activities, continuing operations for fiscal 2015 was -$43.49M.
- Alkermes plc. net cash provided by (used in) investing activities, continuing operations for fiscal 2014 was -$263.40M.
- Alkermes plc. net cash provided by (used in) investing activities, continuing operations for fiscal 2013 was -$177.19M.
| Period end | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month |
|---|---|---|---|---|
| 2017-03-31 | $15.46M 10-Q · filed 2017-04-27 | -$5.42M derived: sum of 2 quarters · filed 2017-04-27 | $41.57M derived: sum of 3 quarters · filed 2017-04-27 | $70.01M derived: sum of 4 quarters · filed 2017-04-27 |
| 2016-12-31 | -$20.88M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-17 | $26.11M derived: sum of 2 quarters · filed 2017-02-17 | $54.55M derived: sum of 3 quarters · filed 2017-02-17 | $127.24M 10-K · filed 2017-02-17 |
| 2016-09-30 | $46.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-02 | $75.43M derived: sum of 2 quarters · filed 2016-11-02 | $148.12M 10-Q · filed 2016-11-02 | $105.90M derived: sum of 4 quarters · filed 2017-04-27 |
| 2016-06-30 | $28.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-07-28 | $101.13M 10-Q · filed 2016-07-28 | $58.91M derived: sum of 3 quarters · filed 2017-04-27 | $89.42M derived: sum of 4 quarters · filed 2017-04-27 |
| 2016-03-31 | $72.69M 10-Q · filed 2017-04-27 | $30.48M derived: sum of 2 quarters · filed 2017-04-27 | $60.99M derived: sum of 3 quarters · filed 2017-04-27 | $58.00M derived: sum of 4 quarters · filed 2017-04-27 |
| 2015-12-31 | -$42.22M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-17 | -$11.71M derived: sum of 2 quarters · filed 2017-02-17 | -$14.70M derived: sum of 3 quarters · filed 2017-02-17 | -$43.49M 10-K · filed 2017-02-17 |
| 2015-09-30 | $30.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-02 | $27.52M derived: sum of 2 quarters · filed 2016-11-02 | -$1.27M 10-Q · filed 2016-11-02 | $44.86M derived: sum of 4 quarters · filed 2017-02-17 |
| 2015-06-30 | -$2.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-07-28 | -$31.78M 10-Q · filed 2016-07-28 | $14.35M derived: sum of 3 quarters · filed 2017-02-17 | -$49.34M derived: sum of 4 quarters · filed 2017-02-17 |
| 2015-03-31 | -$28.79M 10-Q · filed 2016-04-28 | $17.34M derived: sum of 2 quarters · filed 2017-02-17 | -$46.35M derived: sum of 3 quarters · filed 2017-02-17 | -$19.51M derived: sum of 4 quarters · filed 2017-02-17 |
| 2014-12-31 | $46.13M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-17 | -$17.56M derived: sum of 2 quarters · filed 2017-02-17 | $9.28M derived: sum of 3 quarters · filed 2017-02-17 | -$263.40M 10-K · filed 2017-02-17 |
| 2014-09-30 | -$63.69M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-10-29 | -$36.85M derived: sum of 2 quarters · filed 2015-10-29 | -$309.53M 10-Q · filed 2015-10-29 | -$366.82M derived: sum of 4 quarters · filed 2016-02-25 |
| 2014-06-30 | $26.84M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-07-30 | -$245.83M 10-Q · filed 2015-07-30 | -$303.13M derived: sum of 3 quarters · filed 2016-02-25 | -$305.80M derived: sum of 4 quarters · filed 2016-02-25 |
| 2014-03-31 | -$272.67M 10-Q · filed 2015-04-30 | -$329.97M derived: sum of 2 quarters · filed 2016-02-25 | -$332.64M derived: sum of 3 quarters · filed 2016-02-25 | -$338.04M derived: sum of 4 quarters · filed 2016-02-25 |
| 2013-12-31 | -$57.30M derived: 10-K 9 month − 10-Q 6 month · filed 2016-02-25 | -$59.97M derived: sum of 2 quarters · filed 2016-02-25 | -$65.37M 10-K · filed 2016-02-25 | -$177.19M 10-K · filed 2016-02-25 |
| 2013-09-30 | -$2.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-10-31 | -$8.07M 10-Q · filed 2013-10-31 | -$119.90M 10-Q · filed 2014-10-29 | -$151.20M derived: sum of 4 quarters · filed 2015-02-24 |
| 2013-06-30 | -$5.40M 10-Q · filed 2013-07-25 | -$117.23M 10-Q · filed 2014-07-31 | -$148.53M derived: sum of 3 quarters · filed 2015-02-24 | -$82.90M derived: sum of 4 quarters · filed 2015-02-24 |
| 2013-03-31 | -$111.83M 10-Q · filed 2014-04-30 | -$143.13M derived: sum of 2 quarters · filed 2015-02-24 | -$77.50M derived: sum of 3 quarters · filed 2015-02-24 | -$68.15M 10-K · filed 2015-02-24 |
| 2012-12-31 | -$31.30M derived: 10-K 9 month − 10-Q 6 month · filed 2015-02-24 | $34.33M derived: sum of 2 quarters · filed 2015-02-24 | $43.68M 10-K · filed 2015-02-24 | $22.10M derived: sum of 4 quarters · filed 2015-02-24 |
| 2012-09-30 | $65.64M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-10-31 | $74.98M 10-Q · filed 2013-10-31 | $53.41M derived: sum of 3 quarters · filed 2014-02-27 | $50.88M derived: sum of 4 quarters · filed 2014-02-27 |
| 2012-06-30 | $9.35M 10-Q · filed 2013-07-25 | -$12.23M derived: sum of 2 quarters · filed 2014-02-27 | -$14.76M derived: sum of 3 quarters · filed 2014-02-27 | -$414.63M derived: sum of 4 quarters · filed 2014-02-27 |
| 2012-03-31 | -$21.58M derived: 10-KT 12 month − 10-Q 9 month · filed 2014-02-27 | -$24.11M derived: sum of 2 quarters · filed 2014-02-27 | -$423.98M derived: sum of 3 quarters · filed 2014-02-27 | -$417.16M 10-KT · filed 2014-02-27 |
| 2011-12-31 | -$2.53M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-01-31 | -$402.40M derived: sum of 2 quarters · filed 2013-01-31 | -$395.58M 10-Q · filed 2013-01-31 | |
| 2011-09-30 | -$399.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-11-01 | -$393.05M 10-Q · filed 2012-11-01 | ||
| 2011-06-30 | $6.82M 10-Q · filed 2012-07-26 | |||
| 2011-03-31 | $5.63M 10-K · filed 2013-05-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |